Dritte

Dritte is a stealth-mode biotechnology company focused on the discovery and development of a new class of medicines utilizing molecular glue degraders. The company leverages a proprietary platform to design small molecules that induce targeted protein degradation by recruiting E3 ubiquitin ligases to disease-causing proteins. Dritte's approach aims to address previously "undruggable" targets across a range of therapeutic areas, including oncology and neurodegeneration. By stabilizing protein-protein interactions, the company seeks to create highly selective and potent therapies with improved pharmacological profiles compared to traditional inhibitors.